Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ADI 001

Next Previous
Drug Profile

ADI 001

Alternative Names: ADI-001; ADI-001 CD20 gamma delta CAR-T

Latest Information Update: 02 Jul 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Adicet Bio; Regeneron Pharmaceuticals
  • Developer Adicet Bio
  • Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Lupus nephritis; Non-Hodgkin's lymphoma; Systemic lupus erythematosus
  • Preclinical Systemic scleroderma; Vasculitis
  • Discontinued B-cell lymphoma

Most Recent Events

  • 06 May 2025 Adicet Bio plans to initiate enrolment in the phase-I trial for Systemic sclerosis, Idiopathic inflammatory myopathy, and Stiff person syndrome in third quarter of 2025 (NCT06375993)
  • 01 Apr 2025 Phase-I clinical trials in Systemic lupus erythematosus (Treatment-experienced) in USA (IV) (NCT06375993)
  • 27 Feb 2025 ADI 001 receives Fast Track designation for Systemic scleroderma [IV,Infusion] in USA

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top